AstraZeneca (AZN.US) and Merck (MRK.US) jointly announced positive top-line results from the KOMET Phase 3 clinical trial.

Market IntelTuesday, Nov 12, 2024 8:30 pm ET

1min read

Today, AstraZeneca (AZN.US) and Merck (MRK.US) jointly announced positive top-line results from the KOMET clinical Phase 3 trial. The analysis showed that the companies' jointly developed drug, Koselugo (selumetinib), significantly reduced tumor volume in adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, unresectable plexiform neurofibromas (PNs), meeting the primary endpoint of the trial.

NF1 is a rare, incurable genetic disease caused by mutations in the NF1 gene, which encodes the neurofibromin protein. The gene mutation disrupts the RAS/MAPK signaling pathway (RAS-RAF-MEK-ERK), leading to tumor growth. MEK is a key protein kinase in the RAS/MAPK signaling pathway. Koselugo selectively inhibits MEK1 and MEK2, restoring the disrupted signaling pathway and alleviating the condition of NF1 patients.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.